viewHemoGenyx Pharmaceuticals

Hemogenyx teams up with global pharma company to help further develop CDX antibodies

Hemogenyx will now have access to free technical support and advanced methods of engineering which should aid development of its flagship CDX antibodies

CDX antibodies tackle the pre-transplant, conditioning stage of people with blood cancer

HemoGenyx Pharmaceuticals PLC (LON:HEMO) has signed a deal with an unnamed global pharma company to help develop its CDX antibodies – the company’s flagship treatment for blood cancer.

It is hoped these antibodies will eliminate the need for chemotherapy and radiotherapy by killing only “unwanted” cells and allowing more people who would otherwise be deemed unfit enough to receive a bone marrow transplant.

READ: Hemogenyx aims for blood cancer treatment revolution

The antibodies are currently in pre-clinical trials with a phase I study pencilled in for early next year.

Hemogenyx said Monday’s deal boosts its chances of getting the antibodies into clinical trials and beyond.

Under the agreement, the global pharma company will provide Hemogenyx with free technical support, access to advanced methods of engineering antibodies as well as other things that should aid development.

In return, the pharma company will receive a research licence for anything jointly-developed under the agreement, as well as an option for an exclusive worldwide license to commercially exploit CDX antibodies or any variants, which will be jointly developed under the agreement.

Should the partner not exercise that option, Hemogenyx can license the jointly developed CDX antibodies or any variants.

WATCH: HEMO bosssays progress 'surpassing expectations'

“This agreement provides additional support for our development plans for CDX antibodies, and complements the work that we are already undertaking with our own resources,” said chief executive Vladislav Sandler.

“This close collaboration offers the potential for ongoing value-adding licensing arrangements with a major global pharmaceutical company with the benefit of their global reach and large-scale resources.”

Hemogenyx shares soared 24% to 4.72p.

Quick facts: HemoGenyx Pharmaceuticals

Price: 6.5 GBX

Market: LSE
Market Cap: £28.69 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...


HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read